AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Tuberculosis (TB): (S)-(-)-Cycloserine is effective against Mycobacterium tuberculosis, the bacteria that causes TB. It works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. When used as part of a multidrug regimen, (S)-(-)-cycloserine can help to treat TB infections and prevent the development of drug resistance.
Side Effects: Like all medications, (S)-(-)-cycloserine can cause side effects. Common side effects may include nausea, vomiting, diarrhea, dizziness, headache, confusion, mood changes, and drowsiness. Some individuals may also experience allergic reactions or skin rash while taking (S)-(-)-cycloserine.
Neurological Effects: (S)-(-)-Cycloserine has been associated with neurological side effects, particularly at higher doses or with prolonged use. Neurological side effects may include dizziness, headache, confusion, irritability, anxiety, depression, psychosis, and seizures. Patients should be monitored closely for any signs of neurological side effects while taking (S)-(-)-cycloserine.
Psychiatric Effects: (S)-(-)-Cycloserine has been reported to cause psychiatric side effects in some individuals. These may include mood changes, anxiety, depression, psychosis, and suicidal thoughts or behaviors. Patients with a history of psychiatric disorders should be closely monitored for any changes in mood or behavior while taking (S)-(-)-cycloserine.
Renal Impairment: (S)-(-)-Cycloserine is primarily excreted by the kidneys, so patients with renal impairment may require dosage adjustments or closer monitoring to prevent drug accumulation and potential toxicity. Kidney function should be assessed before starting treatment with (S)-(-)-cycloserine, and dosage adjustments may be necessary in patients with impaired renal function.
Drug Interactions: (S)-(-)-Cycloserine may interact with other medications, potentially increasing the risk of side effects or reducing the effectiveness of other drugs. It's important for patients to inform their healthcare providers about all medications, supplements, and herbal products they are taking before starting treatment with (S)-(-)-cycloserine.
Resistance: Like other antibiotics, the overuse or misuse of (S)-(-)-cycloserine can lead to the development of drug-resistant strains of bacteria. It's important to use (S)-(-)-cycloserine judiciously and as part of a multidrug regimen to minimize the risk of resistance development.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| ADHD | 0.1 | 0.1 | |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | -0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergy to milk products | 0.2 | 0.1 | 1 |
| Alopecia (Hair Loss) | 0.1 | 0.1 | |
| Alzheimer's disease | 0.7 | 1.5 | -1.14 |
| Ankylosing spondylitis | 0.1 | 0.2 | -1 |
| Anorexia Nervosa | 0.1 | 0.2 | -1 |
| Antiphospholipid syndrome (APS) | 0.5 | -0.5 | |
| Asthma | 0.2 | -0.2 | |
| Atrial fibrillation | 0.3 | 0.8 | -1.67 |
| Autism | 0.5 | 0.8 | -0.6 |
| Bipolar Disorder | 0.8 | 0.8 | |
| Brain Trauma | 0.2 | -0.2 | |
| Carcinoma | 0.8 | 0.3 | 1.67 |
| Celiac Disease | 0.2 | 0.8 | -3 |
| Cerebral Palsy | 0.2 | -0.2 | |
| Chronic Fatigue Syndrome | 0.3 | 0.3 | 0 |
| Chronic Kidney Disease | 0.5 | 0.5 | |
| Chronic Lyme | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.1 | |
| Colorectal Cancer | 0.3 | 0.3 | |
| Constipation | 0.2 | 0.2 | |
| COVID-19 | 0.3 | 0.6 | -1 |
| Crohn's Disease | 0.8 | 0.3 | 1.67 |
| cystic fibrosis | 0.2 | -0.2 | |
| Depression | 1.2 | 0.3 | 3 |
| Endometriosis | 0.3 | 0.3 | |
| Epilepsy | 0.2 | 0.3 | -0.5 |
| Fibromyalgia | 0.1 | 0.2 | -1 |
| Functional constipation / chronic idiopathic constipation | 0.3 | 0.9 | -2 |
| gallstone disease (gsd) | 0.1 | 0.1 | |
| Generalized anxiety disorder | 0.2 | -0.2 | |
| Graves' disease | 0.3 | 0.3 | |
| Halitosis | 0.2 | 0.2 | |
| Hashimoto's thyroiditis | 0.5 | 0.7 | -0.4 |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 0.1 | 1 |
| hyperglycemia | 0.3 | -0.3 | |
| hypersomnia | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 0.3 | 0.7 | -1.33 |
| Hypoxia | 0.3 | 0.3 | |
| Inflammatory Bowel Disease | 0.2 | 0.3 | -0.5 |
| Insomnia | 0.2 | 0.2 | 0 |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.6 | 0.3 | 1 |
| Liver Cirrhosis | 0.8 | 0.7 | 0.14 |
| Long COVID | 0.7 | 0.8 | -0.14 |
| Lung Cancer | 0.4 | 0.4 | |
| ME/CFS with IBS | 0.2 | -0.2 | |
| ME/CFS without IBS | 0.1 | 0.3 | -2 |
| Metabolic Syndrome | 1.2 | 0.8 | 0.5 |
| Mood Disorders | 1.7 | 0.3 | 4.67 |
| Multiple Sclerosis | 0.6 | 0.4 | 0.5 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | -0.2 | |
| Obesity | 1.5 | 0.3 | 4 |
| obsessive-compulsive disorder | 0.3 | 0.5 | -0.67 |
| Osteoarthritis | 0.2 | 0.2 | |
| Osteoporosis | 0.2 | 0.2 | 0 |
| Parkinson's Disease | 0.6 | 0.6 | |
| Polycystic ovary syndrome | 0.3 | 0.3 | |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| Psoriasis | 0.4 | -0.4 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.8 | 0.2 | 3 |
| Rosacea | 0.2 | 0.2 | |
| Schizophrenia | 0.8 | 0.8 | |
| scoliosis | 0.5 | -0.5 | |
| Sjögren syndrome | 0.1 | 0.3 | -2 |
| Sleep Apnea | 0.2 | -0.2 | |
| Stress / posttraumatic stress disorder | 0.3 | 0.2 | 0.5 |
| Systemic Lupus Erythematosus | 0.8 | 0.8 | |
| Tourette syndrome | 0.2 | -0.2 | |
| Type 1 Diabetes | 0.7 | 0.7 | |
| Type 2 Diabetes | 1.2 | 0.3 | 3 |
| Ulcerative colitis | 0.2 | 0.8 | -3 |
| Unhealthy Ageing | 1 | 1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.